Pancreas adenocarcinoma: Novel therapeutics Journal Article
| Authors: | Krantz, B. A.; Yu, K. H.; O'Reilly, E. M. |
| Article Title: | Pancreas adenocarcinoma: Novel therapeutics |
| Abstract: | Pancreatic ductal adenocarcinoma (PDAC) is the third highest cause of cancer-related deaths in the US, and is projected to be second only to non-small cell lung cancer (NSCLC) by the 2020s. Current therapies have a modest impact on survival and median overall survival (mOS) across all stages of disease remains under a year. Over the last decade, however, great strides have been made in the understanding of PDAC pathobiology including the role of the tumor microenvironment (TME), DNA damage repair and mechanism of immunosuppression. Exciting novel therapeutics are in clinical development targeting the TME to increase cytotoxic drug delivery, decrease immunosuppressive cell presence and attack cancer stem cells (CSCs). Immune checkpoint inhibitors, cancer vaccines and other immunotherapies are actively being studied and novel combinations of targeted agents are being pursued. There is a sense of optimism in the oncology community that these scientific advances will translate into improved outcomes for patients with PDAC in the proximate future. In this review, we examine various novel therapeutics under clinical development with a focus on stromal disrupting agents, immunotherapeutics and DNA damage repair strategies. © Chinese Clinical Oncology. |
| Keywords: | mitogen activated protein kinase; protein kinase b; cancer survival; unclassified drug; overall survival; review; cytotoxic agent; pancreas cancer; t lymphocyte; dna repair; cancer immunotherapy; transforming growth factor beta; sonic hedgehog protein; notch receptor; phosphatidylinositol 3 kinase; monoclonal antibody; chemokine; immunotherapy; cancer vaccine; systematic review; epigenetics; janus kinase; vitamin d; mammalian target of rapamycin; cancer stem cell; pancreas adenocarcinoma; chimeric antigen receptor; tumor immunity; immunomodulating agent; indoleamine 2,3 dioxygenase; beta catenin; wnt protein; focal adhesion kinase; therapeutics; stat protein; tumor microenvironment; phase 2 clinical trial (topic); phase 3 clinical trial (topic); phase 1 clinical trial (topic); antibody conjugate; clinical outcome; immune checkpoint inhibitor; human; tumor microenvironment (tme) |
| Journal Title: | Chinese Clinical Oncology |
| Volume: | 6 |
| Issue: | 3 |
| ISSN: | 2304-3865 |
| Publisher: | AME Publishing Company |
| Date Published: | 2017-06-01 |
| Start Page: | 30 |
| Language: | English |
| DOI: | 10.21037/cco.2017.06.14 |
| PROVIDER: | scopus |
| PUBMED: | 28705007 |
| DOI/URL: | |
| Notes: | Review -- Export Date: 2 August 2017 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work